Overcoming implementation challenges of personalized cancer therapy.
about
Cell-free circulating tumor DNA in cancerSynthetic therapeutic gene circuits in mammalian cellsProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyAn updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versaDelivery of a Protease-Activated Cytolytic Peptide Prodrug by Perfluorocarbon Nanoparticles.Pragmatic medicine in solid cancer: a translational alternative to precision medicineAttitudes regarding privacy of genomic information in personalized cancer therapySMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancersDistribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer.A Novel Methodology using CT Imaging Biomarkers to Quantify Radiation Sensitivity in the Esophagus with Application to Clinical Trials.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014.Evolving Personalized Therapy for Castration-Resistant Prostate Cancer.Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicineConcordance of genomic alterations between primary and recurrent breast cancer.New horizons in tumor microenvironment biology: challenges and opportunitiesPreclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary culturesPatient knowledge and information-seeking about personalized cancer therapy.An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumorsBuilding a personalized medicine infrastructure at a major cancer center.Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.Identifying molecular drivers of gastric cancer through next-generation sequencing.Integration of cancer genomics with treatment selection: from the genome to predictive biomarkersAn appraisal of drug development timelines in the Era of precision oncology.Clinical relevance of target identity and biology: implications for drug discovery and development.Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment.Tumor heterogeneity in the clinic: is it a real problem?Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.The changing landscape of phase I trials in oncology.(99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study.Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs.Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.Pathology, proteomics and the pathway to personalised medicine.A Convergence-Based Framework for Cancer Drug Resistance.
P2860
Q26750899-64B60CAB-C009-4A37-A2FC-9A18D8B536F2Q26826954-48F743BF-EF48-4FA8-ACFD-41625EE48C45Q27025344-981BAC49-5065-4012-ABFD-82315EEB804DQ27027592-A3529C29-16B9-409E-9B31-615984D5B5EFQ27301457-DBEFB69A-F89F-442C-8FFE-6EB861856672Q28391863-952FDD8B-75AB-4E29-989C-8266B91CE7FEQ28655533-E25603DA-7737-44C3-ACC3-3B1896FC6A05Q28818608-5DFDF056-6E34-4F49-A222-82CA0B8C05F6Q33833750-88578BA0-E345-4FEB-9E58-49720579729EQ33920822-84142967-4BAD-4E71-8951-790AC7F6B81DQ34026161-EFA439DC-6BD9-436B-8BA5-CC132A844B24Q34372834-4692EB1B-48A8-4928-A931-58062A5F581AQ34691562-112C1657-DECA-42F0-AEDB-ABA8B977545AQ35083593-503CE398-2A0D-4432-9B9C-60D726FC1F12Q35142440-44B0844A-66FA-4FA2-ACFE-F7A3574E26B4Q35151324-7F03101C-E54C-472E-846A-006BBAAC49CFQ35291231-CB43D05B-E7B8-41FA-B701-A3799EE72651Q36682093-4D05D7F3-ADE1-463E-AEE3-7AB740C80BB0Q36779225-6D86430C-B8AE-4077-AB62-424ECC70DFAAQ36929987-649DF8AB-66D7-459B-BDE0-62698DD170D3Q37034545-563DB13E-8781-40BD-9B7C-91E32C242D7DQ37220383-3B00C57F-0A0B-4DCA-812D-67F776137369Q37301452-B42FB10F-19B9-4C5B-8534-F27D55B595C1Q37416397-29822D5C-6E95-492F-BB5D-3213CEB0C2CCQ37595614-116AD0B0-135B-44B8-A906-071064164EE2Q37619700-1E949E9F-D343-4745-A71D-A4CAD74264E8Q38147723-BCDF71D5-7F2D-49EC-8BBD-76D2E0C9DB24Q38184981-6BF81D6D-56A0-4D37-B1D5-541C376F9DB4Q38192631-BCC45A75-19A4-4893-AF8D-5D36A315B50EQ38319572-CBBAA509-B5A7-4263-83BC-D5013107E333Q38524502-946595FC-F0D1-41AE-815F-8E51F4AEE5CBQ38629203-0354341C-070A-4E5F-844B-21D42FDF6ACBQ39173262-A0520132-C78F-4721-9FBD-1ACA1BD4485BQ41421416-0479B6DE-10A7-47CF-93AE-10D7FDA311D3Q45788551-BDC3AA4F-2600-48C5-93F1-67F319A20082Q47131999-0FB6746B-DAF4-4A5B-87C0-8474B0746097Q47196503-E8BAF069-0F97-4834-907F-3655FB22CD74Q53682041-51CD5A41-3E83-48A6-9444-E842D3CD1F52
P2860
Overcoming implementation challenges of personalized cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overcoming implementation challenges of personalized cancer therapy.
@en
type
label
Overcoming implementation challenges of personalized cancer therapy.
@en
prefLabel
Overcoming implementation challenges of personalized cancer therapy.
@en
P2860
P1476
Overcoming implementation challenges of personalized cancer therapy.
@en
P2093
Gordon B Mills
P2860
P304
P356
10.1038/NRCLINONC.2012.127
P407
P577
2012-07-31T00:00:00Z